Echo Therapeutics Inc. in Franklin, Massachusetts says it received a notice of allowance from the U.S. Patent Office on the methods for using its continuous non-invasive glucose monitoring system. A notice of allowance indicates that the patent application has not been successfully contested and the company may proceed with registering the patent.
Echo Therapeutics is a medical device company that specializes in technologies that deliver drugs through the skin, rather than injections using needles. The company’s Symphony tCGM System (pictured right) , to which the patented methods will apply, is a needle-free, wireless, transdermal — through the skin — continuous glucose monitoring system to provide real-time blood glucose data. The device includes a transdermal sensor, wireless tranceiver, and data display technologies.
The patent covers the method for using the Symphony tCGM System in a hospital critical care setting. It describes a device that graphs a patient’s glucose over time, provides for hypo- and hyperglycemic alarms, displays the glucose trend and rate of change, and allows set points for insulin delivery. The application also covers a miniature transdermal glucose sensor, affixed over an area of permeated skin, that transmits to the monitor.
Read more: Technology in Development to Ease Diabetes Glucose Testing
* * *